Melomanes Combination therapy for the treatment of metastatic melanoma using magnetic nanoparticles
- Coordinator
- Centre National De La Recherche Scientifique CNRS, France
- Runs
- 1 March 2023 to 28 February 2027
- Status
- Running
- EU funding
- €2.7m
- Total cost
- —
- Partners
- 26 organisations in 11 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101073025
What the project is doing
In the project's own words, from its summary on CORDIS.
Metastatic melanoma is a hard-to-treat disease and it remains as one of the most worrisome cancer. There is an urgent need to improve the current therapies (chemotherapy, radiotherapy) that have a limited efficacy. A single therapy is not efficient to tackle metastatic melanoma and a combination of therapies is thus emerging as a necessity to efficiently eradicate all cancer cells. Recently, the development of immunotherapies has shown promises, in particular chimeric antigen receptor (CAR)-T cells.
Nevertheless, the physical barriers represented by cellular and non-cellular components of the tumor microenvironment combined to the abnormal tumor vasculature and high interstitial fluid pressure, hamper an efficient tumour infiltration of CAR-T cells. In this context, thanks to a network of 18 partners (including 10 non-academic partners), MELOMANES aims to train doctoral researchers for the development of a combined therapy exploiting the properties of magnetic nanoparticles to induce damage on the tumor microenvironment by magnetic and optic hyperthermia in order to facilitate the infiltration of CAR-T cells.
This therapeutic approach combining hyperthermia and immunotherapy is versatile, as it could be also applied to other types of solid tumors. Research and transferable training of the doctoral researchers will be performed in a highly interdisciplinary, intersectoral, and international environment. In addition to acquiring skills related to the research project, they will be trained also in open science, communication and dissemination, responsible research and innovation, circular economy, ethics, data management, entrepreneurship, marketing, intellectual property, and gender dimension in research.
Their competences will be validated through certification and qualification examination, allowing a new generation of highly skilled doctoral researchers to emerge with a high-level training in particular in the multidisciplinary field of nanomedicine.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Centre National De La Recherche Scientifique CNRS | Paris | France | Coordinator |
| Ecqa GmbH | Krems An Der Donau | Austria | Associatedpartner |
| Lithoz GmbH | Wien | Austria | Associatedpartner |
| Universitat Wien | Wien | Austria | Participant |
| Pepric NV | Leuven | Belgium | Associatedpartner |
| Eidgenoessische Technische Hochschule Zuerich | Zuerich | Switzerland | Associatedpartner |
| Eidgenossische Materialprufungs- Und Forschungsanstalt | Dubendorf | Switzerland | Associatedpartner |
| Novamechanics Limited | Nicosia | Cyprus | Participant |
| The Cyprus Institute | Nicosia | Cyprus | Associatedpartner |
| Fundacio Institut Catala De Nanociencia I Nanotecnologia | Bellaterra (Barcelona) | Spain | Associatedpartner |
| Fundacion Instituto De Investigacion Marques De Valdecilla | Santander | Spain | Participant |
| Universidad De Cantabria | Santander | Spain | Associatedpartner |
| Misvik Biology Oy | Turku | Finland | Participant |
| Turun Yliopisto | Turku | Finland | Associatedpartner |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Associatedpartner |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Invectys | Paris | France | Participant |
| Universite De Strasbourg | Strasbourg | France | Associatedpartner |
| Universite Paris Cite | Paris | France | Associatedpartner |
| Malsch Neelina | Utrecht | Netherlands | Associatedpartner |
| Stichting Vu | Amsterdam | Netherlands | Participant |
| Oslo Universitetssykehus Hf | Oslo | Norway | Participant |
| Universitetet I Oslo | Oslo | Norway | Associatedpartner |
| First Five Consulting, S.A. | Lisboa | Portugal | Associatedpartner |
| Cn Bio Innovations Limited | Thame | United Kingdom | Associatedpartner |
| Nanotherics | Keele Newcastle Under Lyme | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI